BRSK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL708227	0.44	5/20
SCHEMBL708728	0.54	4/20
Linifanib (SCHEMBL93804)	1.00	3/20
SCHEMBL422640	1.00	3/20
SCHEMBL421934	0.82	3/20
SCHEMBL423819	0.82	3/20
SCHEMBL420765	0.81	3/20
SCHEMBL423705	0.80	3/20
SCHEMBL424019	0.79	3/20
SCHEMBL420207	0.79	3/20
SCHEMBL422603	0.78	3/20
SCHEMBL422778	0.78	3/20
SCHEMBL424914	0.78	3/20
SCHEMBL423390	0.77	3/20
SCHEMBL423713	0.76	3/20
SCHEMBL422415	0.75	3/20
SCHEMBL421603	0.74	3/20
SCHEMBL425370	0.74	3/20
SCHEMBL421654	0.70	3/20
SCHEMBL422629	0.70	3/20

Clinical trials — most relevant to BRSK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds	PHASE2/PHASE3	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma	PHASE2	COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction	PHASE2	ACTIVE_NOT_RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Genetic Predictors of Lithium Response in Bipolar Disorder	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BRSK1 binder may also engage these)

Protein	Name	Similarity
Q5RJI5	—	1.000	Q5RJI5 →
B2DD29	—	1.000	B2DD29 →
Q8CIP4	—	0.997	Q8CIP4 →
Q69Z98	—	0.997	Q69Z98 →
BRSK2	Serine/threonine-protein kinase BRSK2	0.996	landscape →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.996	landscape →
O70405	—	0.994	O70405 →
Q3U1V8	—	0.991	Q3U1V8 →
Q5R7W7	—	0.991	Q5R7W7 →
Q8R0S2	—	0.991	Q8R0S2 →
MARK4	MAP/microtubule affinity-regulating kinase 4	0.991	landscape →
Q68UT7	—	0.991	Q68UT7 →
Q80XI6	—	0.991	Q80XI6 →
Q3U214	—	0.990	Q3U214 →
P98083	—	0.990	P98083 →
O54967	—	0.990	O54967 →
GAK	Cyclin-G-associated kinase	0.990	landscape →
Q9QY01	—	0.990	Q9QY01 →
Q66HA1	—	0.990	Q66HA1 →
A0A0G2JUG7	—	0.990	A0A0G2JUG7 →
Q3ULB5	—	0.989	Q3ULB5 →
D3ZG83	—	0.989	D3ZG83 →
MAP3K10	Mitogen-activated protein kinase kinase kinase 10	0.989	landscape →
MAST3	Microtubule-associated serine/threonine-protein kinase 3	0.989	landscape →
Q9BQI7	—	0.989	Q9BQI7 →
Q641K5	—	0.988	Q641K5 →
D3ZML2	—	0.988	D3ZML2 →
Q9Z0S8	—	0.988	Q9Z0S8 →
Q99KY4	—	0.988	Q99KY4 →
A5PKJ4	—	0.988	A5PKJ4 →